AXIM BIOTECHNOLOGI COM USD0.0001 (AXIM)

11.56
0.44 3.69
OTC
Prev Close 12.00
Open 12.00
Day Low/High 11.50 / 12.07
52 Wk Low/High 0.21 / 19.80
Volume 32.57K
Exchange OTC
Shares Outstanding 52.57B
Market Cap 615.66M
Div & Yield N.A. (N.A)

Latest News

CBS New York Features Medical Marijuana, Inc. Investment Axim® Biotech's Flagship CBD Chewing Gum, IBS Clinical Trial

CBS New York Features Medical Marijuana, Inc. Investment Axim® Biotech's Flagship CBD Chewing Gum, IBS Clinical Trial

Report Features In-Depth Interview with AXIM® CEO and CTO, Highlights Testimonial from CanChew® Customer On Gum's Positive Effects for Chronic Disorders

AXIM® Biotech Expands Advisory Board To Broaden The Development Of Cannabinoids' Therapeutic Indications

AXIM® Biotech Expands Advisory Board To Broaden The Development Of Cannabinoids' Therapeutic Indications

Company Continues to Build World Class Advisory Board Including the Addition of Famed Cardiac Anesthesiologist Dr. Emil Engels MD, MBA, CPC

Axim® Biotech Announces Addition Of World-Renowned Opthamologist To Advisory Board

Axim® Biotech Announces Addition Of World-Renowned Opthamologist To Advisory Board

Company Announces Appointment of Top International Glaucoma Expert to Advise Company's Upcoming Cannabinoid Research

New U.S. Patent Allowance Granted To AXIM® Biotech For Use Of All Cannabinoids In Its Controlled-Release Chewing Gum Products

New U.S. Patent Allowance Granted To AXIM® Biotech For Use Of All Cannabinoids In Its Controlled-Release Chewing Gum Products

Allows Award-Winning Cannabinoid Release Chewing Gum Products to be Used as Delivery Mechanism for All Cannabinoids, Including THC, CBD, CBG, etc.

AXIM® Biotechnologies, Inc. Publishes Product Pipeline Chart For Pharmaceutical Clinical Trials Program In Cannabinoid R&D

AXIM® Biotechnologies, Inc. Publishes Product Pipeline Chart For Pharmaceutical Clinical Trials Program In Cannabinoid R&D

Cannabinoid Innovator's Product Pipeline Highlights Timelines of Its Intellectual Property (IP) Protected Cannabinoid-Based Products from Pre-Clinical to NDA for Multiple Indications

AXIM® Biotechnologies, Inc. Secures Funding To Continue Pharmaceutical Clinical Trials Program In Cannabinoid Research And Development For Multiple Indications

AXIM® Biotechnologies, Inc. Secures Funding To Continue Pharmaceutical Clinical Trials Program In Cannabinoid Research And Development For Multiple Indications

Financing Enables Cannabinoid Innovator to Continue Phase I-II Trials Of Numerous Intellectual Property (IP) Protected Cannabinoid-Based Products

AXIM Biotechnologies, Inc. CEO To Speak At First-Ever National Symposium On Medical Cannabis For Healthcare Professionals In Mexico City

AXIM Biotechnologies, Inc. CEO To Speak At First-Ever National Symposium On Medical Cannabis For Healthcare Professionals In Mexico City

AXIM CEO to Discuss Company's Use of Cannabinoids to Treat Health Conditions with No Known Cure at Symposium Held by Medical Marijuana, Inc.'s HempMeds® Mexico